pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Isturisa
drug
save

osilodrostat phosphate

Marketedupdated 3mo ago
by Recordati Rare Diseases Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval16 co-mentions · 4 sources
  • drugISTURISA16 co-mentions · 4 sources
  • tagRare Disease8 co-mentions · 4 sources
  • tagSmall Molecule8 co-mentions · 4 sources

all catalysts(4)

approval · 4
Mar 6, 2020
approval
6y ago
ISTURISA (OSILODROSTAT PHOSPHATE) — FDA approval
osilodrostat phosphate
→
Apr 15, 2025
approval
1y ago
ISTURISA (OSILODROSTAT PHOSPHATE) — FDA approval
osilodrostat phosphate
→
Jul 3, 2025
approval
1y ago
ISTURISA (OSILODROSTAT PHOSPHATE) — FDA approval
osilodrostat phosphate
→
Nov 4, 2025
approval
10mo ago
ISTURISA (OSILODROSTAT PHOSPHATE) — FDA approval
osilodrostat phosphate
→

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 23, 2026
2 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Oct 12, 2035method-of-use (U-2770)US 10709691
  • Oct 12, 2035method-of-use (U-2770)US 10709691
  • Oct 12, 2035method-of-use (U-2770)US 10709691
  • Jul 6, 2035formulationUS 10143680
  • Jul 6, 2035formulationUS 10143680
  • Jul 6, 2035formulationUS 10143680
  • Jan 13, 2031method-of-use (U-2770)US 86098624.4y
  • Jan 13, 2031method-of-use (U-2770)US 86098624.4y
  • Jan 13, 2031method-of-use (U-2770)US 86098624.4y
  • Jan 13, 2031compositionUS 94347544.4y
  • Jan 13, 2031compositionUS 94347544.4y
  • Jan 13, 2031compositionUS 94347544.4y
  • Mar 27, 2029compositionUS 83140972.6y
  • Mar 27, 2029compositionUS 83140972.6y
  • Mar 27, 2029compositionUS 83140972.6y
  • Aug 23, 2026compositionUS 88356462d
  • Aug 23, 2026compositionUS 88356462d
  • Aug 23, 2026compositionUS 88356462d

FDA exclusivities (3)

  • Mar 6, 2027ODE-286Orphan Drug (7y)197d
  • Mar 6, 2027ODE-286Orphan Drug (7y)197d
  • Mar 6, 2027ODE-286Orphan Drug (7y)197d

News(0)

no news has mentioned this drug yet

brand
Isturisa
generic
osilodrostat phosphate
indication
Pituitary ACTH Hypersecretion (Cushing Disease)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 35m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?